Panel weighs tighter review, citation rules for therapeutic cannabis oversight board
Loading...
Summary
Lawmakers heard competing testimony on SB 400, which would require the Therapeutic Cannabis Medical Oversight Board to conduct scheduled reviews of qualifying medical conditions and include literature citations with recommendations. Supporters said the change would provide clinicians and patients with clearer evidence; the oversight board said mandatory frequent systematic reviews could be onerous and unnecessary.
The committee heard hours of expert testimony on SB 400, a bill that would change statute to require the Therapeutic Cannabis Medical Oversight Board (TCMOB) to perform scheduled reviews of qualifying medical conditions and to include citations supporting any recommendation.
Sponsor representative Grotta introduced the measure on behalf of Senator Gannon. Sue Hamola, who spoke early for the bill, said the change would create an explicit timeline and better documentation for the board’s recommendations: "This bill actually seeks to amend the RSA 1 26 x to have the therapeutic cannabis medical oversight board do a biennial review of qualifying medical conditions," she said, adding that citations are standard medical practice and increase transparency.
Several medical witnesses supported clearer documentation and more timely reviews. Dr. James Kelly, a primary-care physician and New Hampshire Army National Guard medical adviser, urged the board be required to supply sources so clinicians can access the evidence behind changes.
But Jerry Kirk, chair of the TCMOB, told the committee the board already reviews new and existing qualifying conditions, often through subcommittee literature reviews and public hearings, and warned that imposing frequent systematic reviews could be too burdensome for a volunteer board. "In summary, we feel that this bill is not necessary and is perhaps unworkable," he said, emphasizing the time and academic rigor required for high-quality reviews.
Alternative-treatment-center (ATC) representatives raised operational concerns: Matt Simon of Granite Leaf Cannabis said the board’s currently limited meeting schedule and volunteer nature could make the statutory deadlines impractical and could divert resources from other oversight work.
Committee members pressed on what the bill would actually require and whether it would force the TCMOB to perform new studies. Witnesses replied the bill formalizes a timeline for reviews and requires citations with recommendations; it does not compel primary research. The committee did not vote on the bill during this session.
What happens next: The committee may consider amendments to reconcile the sponsor’s transparency goals with the board’s capacity constraints, and may hold a subsequent work session to draft compromise language.
